氟维司群与依西美坦作为中国绝经后雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌一线治疗的临床疗效比较(FRIEND研究)
FRIEND研究为随机、开放标签、多中心、平行对照2期试验,纳入145例既往辅助非甾体芳香化酶抑制剂治疗≥2年的绝经后ER+/HER2-晚期乳腺癌患者,比较氟维司群与依西美坦一线单药疗效。氟维司群组中位无进展生存期8.5个月优于依西美坦组5.6个月(p=0.014,HR=0.62,95%CI 0.42-0.91),客观缓解率19.5% versus 6.0%(p=0.017),两组不良事件发生率几乎相同。
要点
- 氟维司群较依西美坦显著延长中位无进展生存期(8.5 versus 5.6个月,p=0.014,HR=0.62)。
- 氟维司群组客观缓解率19.5% versus 依西美坦组6.0%(p=0.017)。
- 两组不良事件或严重不良事件发生率几乎相同。
核心结论
- 氟维司群显著延长ER+/HER2-晚期乳腺癌患者的总无进展生存期,且耐受性良好。
研究设计与样本
- 随机、开放标签、多中心、平行对照2期FRIEND研究,纳入145例绝经后ER+/HER2-晚期乳腺癌患者。
- 患者既往接受辅助非甾体芳香化酶抑制剂治疗≥2年。
- 氟维司群组77例:500 mg于第0、14、28天给药,之后每28±3天给药;依西美坦组67例:25 mg/日。
- 主要终点为无进展生存期,次要终点包括疾病控制率、客观缓解率、至治疗失败时间、缓解持续时间和总生存期。
主要发现
- 氟维司群组中位无进展生存期8.5个月 versus 依西美坦组5.6个月(p=0.014,HR=0.62,95%CI 0.42-0.91)。
- 氟维司群组客观缓解率19.5% versus 依西美坦组6.0%(p=0.017)。
- 氟维司群组至治疗失败时间8.4个月 versus 依西美坦组5.5个月(p=0.008)。
- 两组不良事件或严重不良事件发生率几乎相同。
- 129例可分析患者中最常见突变为ESR1基因18例(14.0%)、PIK3CA 40例(31.0%)、TP53 29例(22.5%)。
关键数值与推荐
- 氟维司群给药方案:500 mg于第0、14、28天,之后每28±3天给药。
- 依西美坦给药方案:25 mg/日。
- 主要终点无进展生存期:氟维司群组8.5个月 versus 依西美坦组5.6个月(p=0.014,HR=0.62,95%CI 0.42-0.91)。
- 客观缓解率:氟维司群组19.5% versus 依西美坦组6.0%(p=0.017)。
- 至治疗失败时间:氟维司群组8.4个月 versus 依西美坦组5.5个月(p=0.008)。
临床怎么用
- 原文结论为氟维司群显著延长ER+/HER2-晚期乳腺癌患者的总无进展生存期且耐受性良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To compare the efficacies of exemestane and fulvestrant as first-line monotherapies for postmenopausal Chinese women having advanced oestrogen-receptor positive (ER+)/ human epidermal growth factor receptor 2 (HER2)-breast cancer (ER+/HER2- ABC) after a previous treatment for ≥2 years with an adjuvant non-steroidal aromatase inhibitor. METHODS: In this randomised, open-label, multi-centre, parallel-controlled phase 2 FRIEND study, 145 postmenopausal ER+/HER2- ABC patients were assigned into fulvestrant (500 mg on days 0, 14 and 28, and then at every 28 ± 3 days, n = 77) and exemestane (25 mg/day, n = 67) groups. The primary outcome was progression-free survival (PFS), while the secondary outcomes were disease control rate, objective response rate, time to treatment failure, duration of response and overall survival. Exploratory end-points included gene mutation-related outcomes and safety. RESULTS: Fulvestrant was superior to exemestane regarding median PFS times (8.5 versus 5.6 months, p = 0.014, HR = 0.62, 95% confidence intervals: 0.42-0.91), objective response rates (19.5% versus 6.0%, p = 0.017) and time to treatment failure (8.4 versus 5.5 months, p = 0.008). The incidence of adverse or serious adverse events in the two groups was virtually identical. The most frequent mutations in 129 analysed patients were detected in the oestrogen receptor gene 1 (ESR1) (18/14.0%), PIK3CA (40/31.0%) and TP53 (29/22.5%) genes. Fulvestrant produced significant longer PFS times compared to exemestane but only for patients with an ESR1-wild type (8.5 versus 5.8 months) (p = 0.035), although there was a similar trend also for the ESR1 mutation without statistical significance. All patients with c-MYC and BRCA2 mutations had longer PFS times in the fulvestrant versus the exemestane group (p = 0.049, p = 0.039). CONCLUSION: Fulvestrant significantly increased overall PFS for ER+/HER2- ABC patients and was well tolerated. CLINICALTRIALS: NCT02646735, https://clinicaltrials.gov/ct2/show/NCT02646735.
引用
- Wang J, Cai L, Song Y, et al. Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study). Eur J Cancer. 2023. PMID: 36905771. doi:10.1016/j.ejca.2023.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。